KR102660506B1 - 면역억제가 향상된 간충직 계통 전구체 또는 줄기 세포 - Google Patents

면역억제가 향상된 간충직 계통 전구체 또는 줄기 세포 Download PDF

Info

Publication number
KR102660506B1
KR102660506B1 KR1020197035053A KR20197035053A KR102660506B1 KR 102660506 B1 KR102660506 B1 KR 102660506B1 KR 1020197035053 A KR1020197035053 A KR 1020197035053A KR 20197035053 A KR20197035053 A KR 20197035053A KR 102660506 B1 KR102660506 B1 KR 102660506B1
Authority
KR
South Korea
Prior art keywords
cells
cell
delete delete
gvhd
mesenchymal lineage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197035053A
Other languages
English (en)
Korean (ko)
Other versions
KR20200003044A (ko
Inventor
실비우 이떼스쿠
폴 시몬스
Original Assignee
메조블라스트 인터내셔널 에스에이알엘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901633A external-priority patent/AU2017901633A0/en
Application filed by 메조블라스트 인터내셔널 에스에이알엘 filed Critical 메조블라스트 인터내셔널 에스에이알엘
Priority to KR1020247013202A priority Critical patent/KR102884611B1/ko
Publication of KR20200003044A publication Critical patent/KR20200003044A/ko
Application granted granted Critical
Publication of KR102660506B1 publication Critical patent/KR102660506B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020197035053A 2017-05-04 2018-05-04 면역억제가 향상된 간충직 계통 전구체 또는 줄기 세포 Active KR102660506B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247013202A KR102884611B1 (ko) 2017-05-04 2018-05-04 면역억제가 향상된 중간엽 계통 전구체 또는 줄기 세포

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2017901633 2017-05-04
AU2017901633A AU2017901633A0 (en) 2017-05-04 Potency assay for immunosuppression
AU2017901636A AU2017901636A0 (en) 2017-05-04 Method for treating Graft versus Host Disease (GVHD)
AU2017901636 2017-05-04
AU2018900551A AU2018900551A0 (en) 2018-02-21 Potency assay for immunosuppression II
AU2018900551 2018-02-21
PCT/EP2018/061503 WO2018202853A1 (en) 2017-05-04 2018-05-04 Mesenchymal lineage precursor or stem cells with enhanced immunosuppression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247013202A Division KR102884611B1 (ko) 2017-05-04 2018-05-04 면역억제가 향상된 중간엽 계통 전구체 또는 줄기 세포

Publications (2)

Publication Number Publication Date
KR20200003044A KR20200003044A (ko) 2020-01-08
KR102660506B1 true KR102660506B1 (ko) 2024-04-25

Family

ID=62222586

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197035053A Active KR102660506B1 (ko) 2017-05-04 2018-05-04 면역억제가 향상된 간충직 계통 전구체 또는 줄기 세포
KR1020247013202A Active KR102884611B1 (ko) 2017-05-04 2018-05-04 면역억제가 향상된 중간엽 계통 전구체 또는 줄기 세포

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247013202A Active KR102884611B1 (ko) 2017-05-04 2018-05-04 면역억제가 향상된 중간엽 계통 전구체 또는 줄기 세포

Country Status (10)

Country Link
US (1) US20200325450A1 (https=)
EP (2) EP4137562A1 (https=)
JP (3) JP7398959B2 (https=)
KR (2) KR102660506B1 (https=)
CN (1) CN110753751A (https=)
AU (2) AU2018262788B2 (https=)
BR (1) BR112019022901A2 (https=)
CA (1) CA3062112A1 (https=)
SG (1) SG11201909856XA (https=)
WO (1) WO2018202853A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
SI2785359T1 (sl) 2011-11-30 2018-11-30 Astellas Institute For Regenerative Medicine Mezenhimske stromalne celice in uporabe povezane z njimi
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
HK1208054A1 (en) 2012-07-12 2016-02-19 爱姆斯坦生物技术公司 Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
SG11201909856XA (en) * 2017-05-04 2019-11-28 Mesoblast Int Sarl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
KR20220143092A (ko) * 2020-02-19 2022-10-24 메조블라스트 인터내셔널 에스에이알엘 만성 이식편 대 숙주 질환의 치료 방법
JP7793284B2 (ja) * 2020-03-02 2026-01-05 株式会社ガイアバイオメディシン 高活性ｎｋ細胞の処理方法
JP2023530098A (ja) * 2020-06-11 2023-07-13 メゾブラスト・インターナショナル・エスアーエールエル 間葉系前駆細胞又は幹細胞の３ｄ培養
AU2021323475A1 (en) * 2020-08-10 2023-04-13 Mesoblast International Sarl A composition comprising mesenchymal precursor or stem cells and their use
CN112444479B (zh) * 2021-02-01 2021-05-07 宁波大学 基于并行处理技术的单细胞质谱分析系统及方法
CN113881707B (zh) * 2021-10-25 2023-07-14 中国人民解放军军事科学院军事医学研究院 调控脐带间充质干细胞免疫抑制作用的产品、方法及用途
US20250032552A1 (en) * 2021-12-23 2025-01-30 Mesoblast International Sárl Method of treating severe graft versus host disease
CA3260880A1 (en) * 2022-07-05 2024-01-11 Mesoblast International Sarl CRYOPROVERTED INTERMEDIATE AND BIOLOGICAL ACTIVITY TEST FOR IT
KR20250049337A (ko) 2022-08-09 2025-04-11 엑손모빌 케미칼 패턴츠 인코포레이티드 디페닐실란 가교 c1 대칭 촉매의 제조 방법 및 이로부터 제조된 중합체
WO2024168161A1 (en) * 2023-02-08 2024-08-15 Mesoblast International Sarl Potency assay and manufacturing method
WO2025196663A1 (en) * 2024-03-19 2025-09-25 Mesoblast International Sarl Potency assay and manufacturing method ii
CN118147232B (zh) * 2024-05-09 2024-07-19 中国人民解放军联勤保障部队第九二〇医院 一种过表达tps1间充质干细胞的构建方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140112893A1 (en) * 2010-10-08 2014-04-24 Mesoblast International Sarl Enhanced msc preparations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593089A (en) 1980-07-30 1986-06-03 Abbott Laboratories Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
US4751190A (en) 1985-07-22 1988-06-14 Abbott Laboratories Fluorescence polarization immunoassay and reagents for use therein
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
DE4211351A1 (de) 1992-04-04 1993-10-07 Behringwerke Ag Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung
WO1994026877A1 (en) 1993-05-17 1994-11-24 The Regents Of The University Of California Ribozyme gene therapy for hiv infection and aids
US6541213B1 (en) 1996-03-29 2003-04-01 University Of Washington Microscale diffusion immunoassay
CA2244326C (en) 1997-08-11 2006-03-28 Shinichi Eda Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor
US6566051B1 (en) 1999-01-15 2003-05-20 Medtox Scientific, Inc. Lateral flow test strip
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US7205159B2 (en) 2001-08-20 2007-04-17 Proteome Systems Intellectual Property Pty Ltd. Diagnostic testing process and apparatus
WO2004046729A2 (en) 2002-11-21 2004-06-03 The University Of Leicester Bodily fluid markers of tissue hypoxia
CN101248171B (zh) 2005-04-12 2015-11-25 迈索布拉斯特股份有限公司 通过组织非特异性碱性磷酸酶分离成人多潜能细胞
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
KR101891260B1 (ko) * 2010-07-02 2018-08-24 메소블라스트, 아이엔씨. T-세포 매개된 면역 질환의 치료
KR20150016117A (ko) * 2013-07-30 2015-02-11 코아스템(주) 인간 골수 유래 중간엽 줄기세포를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약제학적 조성물
SG11201607925SA (en) * 2014-04-07 2016-10-28 Mesoblast Internat Sarl Improved stem cell composition
EP3236977B1 (en) * 2014-12-23 2023-06-21 Mesoblast International Sàrl Method for treating heart failure
SG11201909856XA (en) 2017-05-04 2019-11-28 Mesoblast Int Sarl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140112893A1 (en) * 2010-10-08 2014-04-24 Mesoblast International Sarl Enhanced msc preparations

Also Published As

Publication number Publication date
JP2020518260A (ja) 2020-06-25
WO2018202853A1 (en) 2018-11-08
EP4137562A1 (en) 2023-02-22
KR102884611B1 (ko) 2025-11-12
SG11201909856XA (en) 2019-11-28
EP3619294A1 (en) 2020-03-11
US20200325450A1 (en) 2020-10-15
AU2018262788B2 (en) 2024-08-15
KR20200003044A (ko) 2020-01-08
JP2026034487A (ja) 2026-02-27
JP7787130B2 (ja) 2025-12-16
JP2023174760A (ja) 2023-12-08
JP7398959B2 (ja) 2023-12-15
BR112019022901A2 (pt) 2020-05-19
CA3062112A1 (en) 2018-11-08
AU2024227344A1 (en) 2024-10-31
CN110753751A (zh) 2020-02-04
KR20240056790A (ko) 2024-04-30
AU2018262788A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
JP7787130B2 (ja) 向上した免疫抑制作用を有する間葉系前駆または幹細胞
Li et al. Thymus-homing peripheral dendritic cells constitute two of the three major subsets of dendritic cells in the steady-state thymus
KR20210099573A (ko) 개선된 종양 반응성 t-세포의 선택
JP6315989B2 (ja) Ｔ細胞性免疫不全の治療法
WO2018229163A1 (en) Methods of activating v delta 2 negative gamma delta t cells
KR20180033537A (ko) Pd-l1 발현 조혈 줄기 세포 및 용도
JP2023524108A (ja) 改良された腫瘍反応性ｔ細胞の選択
KR101786862B1 (ko) 류마티즘성 질환을 치료 또는 예방하는 방법
JP2025521740A (ja) 凍結保存中間体及びそれに対する効力アッセイ
HK40088319A (en) Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
CN117480246A (zh) 用于t细胞共培养物效力测定和配合细胞疗法产品使用的方法和组合物
US20180139937A1 (en) Cell culture systems for producing il-33 induced t9 cells and methods of using the cells
WO2022204564A2 (en) Methods and compositions for t-cell coculture potency assays and use with cell therapy products
EP4045064A1 (en) Treatment of autoimmunity and transplant rejection through establishment and/or promotion of tolerogenic processes by fibroblast-mediated reprogramming of antigen presenting cells
JP2026504544A (ja) 効力アッセイ、及び製造方法
Simonetta et al. Moving Towards Allogeneic Cellular Therapies: Opportunities and Challenges

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601